NASDAQ:CALA Calithera Biosciences (CALA) Stock Price, News & Analysis $0.0002 0.00 (0.00%) As of 05/22/2026 02:33 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock About Calithera Biosciences Stock (NASDAQ:CALA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Calithera Biosciences alerts:Sign Up Key Stats Today's Range$0.0002▼$0.000250-Day Range N/A52-Week Range$0.0001▼$0.0038Volume550 shsAverage Volume763 shsMarket Capitalization$772.00P/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Calithera Biosciences, Inc. is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The company is focused on the discovery and development of small molecule inhibitors that target metabolic pathways critical to the growth and survival of cancer cells. By disrupting tumor metabolism, Calithera aims to create novel therapeutic options for patients with solid tumors and hematologic malignancies. The company’s pipeline includes lead candidates such as telaglenastat (CB-839), a glutaminase inhibitor being evaluated in multiple Phase 2 trials across various tumor types, and CB-1158, an arginase inhibitor designed to reprogram the tumor microenvironment and enhance anti-tumor immunity. Calithera also maintains discovery programs exploring additional metabolic targets, leveraging its proprietary chemistry and extensive biomarker capabilities to advance new compounds from preclinical research into the clinic. Founded in 2008, Calithera completed its initial public offering in 2014 and has since established strategic collaborations with global partners to support clinical development and commercialization. The company operates primarily in the United States but conducts clinical trials and collaborates with research centers in Europe and Asia, reflecting its commitment to developing therapies that can address cancer care needs worldwide. Calithera’s leadership team combines expertise in oncology drug development, translational biology, and regulatory affairs. The executive management and board members bring experience from both pharmaceutical companies and research institutions, guiding the company’s efforts to translate metabolic insights into innovative treatments for patients battling cancer.AI Generated. May Contain Errors. Read More Receive CALA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Calithera Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CALA Stock News HeadlinesCalithera Biosciences Inc (CALA)November 23, 2024 | investing.comPrimecap Management Portfolio Exposed: Top Holdings RevealedApril 26, 2024 | msn.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.May 26 at 1:00 AM | Porter & Company (Ad)Arcus Biosciences Inc (RCUS)February 24, 2024 | uk.investing.comChristina CalaAugust 12, 2023 | npr.orgNCalithera Biosciences cancels special meeting due to lack of quorumJune 29, 2023 | seekingalpha.comCALA - Calithera Biosciences, Inc.May 31, 2023 | finance.yahoo.comCalithera Biosciences, Inc.: Calithera Biosciences Announces Update on Complete Liquidation and DissolutionMay 20, 2023 | finanznachrichten.deSee More Headlines CALA Stock Analysis - Frequently Asked Questions How have CALA shares performed this year? Calithera Biosciences' stock was trading at $0.0001 on January 1st, 2026. Since then, CALA stock has increased by 100.0% and is now trading at $0.0002. How were Calithera Biosciences' earnings last quarter? Calithera Biosciences, Inc. (NASDAQ:CALA) posted its earnings results on Monday, November, 8th. The biotechnology company reported ($3.00) earnings per share for the quarter, topping the consensus estimate of ($4.60) by $1.60. The biotechnology company earned $6.75 million during the quarter. When did Calithera Biosciences' stock split? Calithera Biosciences's stock reverse split on Wednesday, June 15th 2022.The 1-20 reverse split was announced on Wednesday, June 15th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, June 15th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Calithera Biosciences? Shares of CALA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Calithera Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Calithera Biosciences investors own include Puma Biotechnology (PBYI), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Dynavax Technologies (DVAX) and First Solar (FSLR). Company Calendar Last Earnings11/08/2021Today5/26/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CALA CIK1496671 Webwww.calithera.com Phone(650) 870-1000FaxN/AEmployees60Year Founded2010Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares3,860,000Free Float4,550,000Market Cap$772.00 OptionableNot Optionable Beta-1.05 Social Links 7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:CALA) was last updated on 5/26/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredThe SpaceX supplier that shipped 5 billion chips to StarlinkWhen Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...Weiss Ratings | SponsoredThe S-1 just dropped. 22 days left.The SpaceX S-1 is now public - $18.7 billion in revenue, a $75 billion raise, and a June 12 Nasdaq listing con...Behind the Markets | SponsoredMy crisis of conscienceEmmet Savage - named in Irish America's Wall Street 50 as one of the most successful investors in the world - ...Porter & Company | SponsoredBetter than SpaceX? Grab this ticker instead.Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...Brownstone Research | SponsoredYour book attachedBill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...Profits Run | SponsoredTrump Admin to Pump $1 Billion into this “Off-the-Radar” AI StockThe U.S. government pumped more than $1 billion into Intel. The stock popped 128%. It pumped $400 million into...InvestorPlace | SponsoredOpportunity Forming in a U.S. Supply-Chain Weak Spot?America has a supply-chain problem with graphite - demand is climbing while dependence on foreign sources rema...i2i Marketing Group, LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Calithera Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Calithera Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
